The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

Inclusion Criteria: Individuals with type 2 diabetes newly diagnosed based on the WHO (1999) criteria; Hemoglobin A1c levels >=7.0% and <=8.0%; Females or males ≥18 years up to 75 years of age. Exclusion Criteria: Females or males <18 years. Clinical diagnosis of type 1 diabetes and other types of diabetes. Blood pressure at screening that would require a change in blood pressure treatment over the study period. History of stroke or other clinically significant cerebrovascular disease. Any of the following cardiovascular diseases: Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function Unstable heart failure or any heart failure with NYHA class III and IV Significant valvular disease Significant peripheral artery disease Active malignancy requiring treatment at the time of visit 0. Patients with severe hepatic impairment. Unstable or rapidly progressing renal disease. Ongoing treatment with loop diuretics. Estimated Glomerular Filtration Rate (eGFR) <45 mL/min/1.73 m2. Women who has a positive pregnancy test at enrolment or randomization, or are breastfeeding.